Clinical study to elucidate the efficacy of oral propranolol treatment for infantile hemangiomas
Not Applicable
- Conditions
- Infantile hemangiomas
- Registration Number
- JPRN-UMIN000012123
- Lead Sponsor
- Juntendo University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patient who has a severe complication without infantile hemangiomas 2.Patient with the past of serious side effect by the propranolol drug 3.Patient with cardiac disease, asthma or carbohydrate metabolism 4.Patient who was considered ineligible by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in color and size of infantile hemangiomas, and side effects of propranolol treatment
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain propranolol's efficacy in infantile hemangiomas regression?
How does oral propranolol compare to laser therapy in treating proliferative infantile hemangiomas?
Are there specific biomarkers that predict response to propranolol in segmental hemangiomas cases?
What are the most common adverse events associated with propranolol treatment in neonates and infants?
What combination therapies with propranolol show promise for complex infantile hemangiomas treatment?